Welcome to our dedicated page for DAVITA SEC filings (Ticker: DVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DaVita Inc. filings document the operating results, governance and capital structure of a public kidney care and dialysis services company. Its 8-K reports furnish quarterly financial results, including revenue, operating income, per-share results, cash flow measures, treatment economics and share repurchase activity.
Proxy filings cover board matters, executive compensation, shareholder voting items and governance disclosures. Other current reports record material financing arrangements, amendments to secured credit facilities, share repurchase authorizations and the company's common stock listing on the New York Stock Exchange under DVA.
DaVita Inc.’s CFO and Treasurer Joel Ackerman reported an open-market sale of 51,471 shares of DaVita common stock. The transaction occurred on May 7, 2026 at a weighted average price of $192.099 per share, with individual sale prices ranging from $191.510 to $192.765. Following this sale, Ackerman directly holds 132,434 shares of DaVita common stock.
DaVita Inc. Chief Compliance Officer James O. Hearty reported an open-market sale of Common Stock. On May 6, 2026, he sold 2,184 shares at $174.87 per share. After this transaction, he directly owned 35,953 shares of DaVita common stock. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 15, 2025, indicating the trades were scheduled in advance.
DaVita Inc. reported proposed sales of Common Stock under a Form 144 via UBS Financial Services Inc. The filing lists multiple blocks of shares tied to employee equity events, including awards and option exercises on 03/15/2025, 03/15/2024, 09/16/2024, 05/10/2023, and 05/15/2023.
The broker named is UBS Financial Services Inc. and the shares are listed on the NYSE. The filing documents planned dispositions of specific share counts associated with those grant/exercise dates (examples shown below).
DaVita Inc. insider filing shows a large share sale by Berkshire Hathaway–related entities. An entity associated with Berkshire completed an open-market sale of 1,220,376 shares of DaVita common stock at an average price of $149.8429 per share. After this transaction, Berkshire-associated holdings reported in the filing total 28,880,209 DaVita shares, held indirectly.
The filing explains that 13,906,601 of these shares are owned by Government Employees Insurance Company, a Berkshire subsidiary, and 14,973,608 shares are owned by pension plans of Berkshire subsidiaries. Berkshire and Warren E. Buffett disclaim beneficial ownership in certain shares except to the extent of any pecuniary interest.
DaVita Inc. reported higher results for the three months ended March 31, 2026, with total revenues of $3,415.5M versus $3,223.5M a year earlier. Net income attributable to DaVita rose to $197.5M from $162.9M, and diluted EPS increased to $2.87 from $2.00.
U.S. dialysis remained the core business, generating $2,941.7M of revenue and operating income of $506M, while ancillary services produced $498M of revenue and modest operating income of $6M. Consolidated operating income grew to $481.9M from $438.9M.
Operating cash flow strengthened to $320.8M from $180.0M, supporting capital spending of $102.0M and share repurchases of 3.0 million shares for $402.9M. Long-term debt totaled $10,626.3M in principal, and DaVita signed an agreement to buy a roughly $200M minority stake in Elara Caring, pending customary approvals.
DaVita Inc. reported solid results for the quarter ended March 31, 2026, with consolidated revenues of $3.416 billion and operating income of $482 million, reflecting a higher operating margin of 14.1% versus 13.6% a year earlier.
Net income attributable to DaVita was $197.5 million, or $2.87 in diluted earnings per share from continuing operations, up from $2.00 a year ago. Operating cash flow rose to $321 million, and free cash flow improved to $140 million from a negative $45 million in the prior-year quarter.
U.S. dialysis treatment volume was 7.03 million, with average patient service revenue per treatment of $417.59. The company was serving about 296,300 patients at 3,262 centers worldwide and had roughly 62,600 patients in risk-based integrated kidney care arrangements representing $5.4 billion in annualized medical spend.
DaVita continued returning capital, repurchasing 3.0 million shares for $403 million in the quarter and another 2.0 million shares for $302 million through May 5, 2026. Management reaffirmed 2026 free cash flow guidance and modestly raised ranges for adjusted operating income and adjusted diluted EPS.
DaVita Inc. is asking stockholders to vote at its virtual-only 2026 annual meeting on three key items: electing nine director nominees, ratifying KPMG LLP as independent auditor for 2026, and approving on an advisory basis the compensation of named executive officers.
The board highlights strong governance, including an independent chair, annual director elections, majority voting in uncontested elections, proxy access for long-term holders, and the right for 10% stockholders to call special meetings. Eight of nine nominees are independent under NYSE standards, and board refreshment is guided by mandatory retirement and overboarding limits.
The company reports 2025 performance in line with long-term financial targets for adjusted operating income growth of 3–7% and adjusted diluted EPS growth of 8–14%. It also emphasizes ESG results such as empowering 8,000+ patients to receive kidney transplants, saving over 90 million gallons of water, teammate engagement of 85%, and exceeding its five-year volunteerism goal with more than 70,000 hours contributed in 2025.
The Vanguard Group amended its Schedule 13G for DaVita Inc. to report 0 shares of Common Stock following an internal realignment effective January 12, 2026. The filing states certain subsidiaries will report beneficial ownership separately and that Vanguard no longer is deemed to beneficially own those securities. The amendment is signed by Ashley Grim on March 26, 2026.